Cholinergic receptor nicotinic beta 1 subunit (CHRNB1) (CHRNB1)

Cholinergic receptor nicotinic beta 1 subunit (CHRNB1) encodes the β1 subunit of the muscle-type nicotinic acetylcholine receptor (AChR), a pentameric ligand-gated ion channel that forms a heteropentamer with two alpha, one beta, one gamma (fetal), or epsilon (adult), and one delta subunit[2]. This receptor is essential for synaptic transmission at the neuromuscular junction, where binding of acetylcholine released by motor neurons induces a conformational change, opening the channel, depolarizing the muscle membrane, and triggering muscle contraction[1][3]. CHRNB1 is crucial for both effective neuromuscular transmission and processes in fetal development, notably muscle movement. Mutations in CHRNB1 are associated with congenital myasthenic syndromes (slow-channel and acetylcholine receptor deficiency subtypes) and fetal akinesia deformation sequence[1][3]. Emerging genetic studies also suggest a possible role in susceptibility to nicotine dependence, indicating a broader influence on cholinergic signaling beyond the neuromuscular junction[1]. Consistent with its classification, CHRNB1 is a bona fide ion channel and receptor target, but there are currently no drugs in clinical use that selectively target this subunit—most therapies target the receptor complex as a whole.

Other names

Acetylcholine receptor subunit betaCHRNB1ACHRBCHRNBacetylcholine receptor nicotinic beta 1 (muscle)cholinergic receptor nicotinic beta 1cholinergic receptor nicotinic beta polypeptide 1 (muscle)CMS1DCMS2ACMS2CSCCMS

Ligand binding (acetylcholine) induces receptor conformational change and opening of an ion-conducting channel, facilitating synaptic transmission and muscle contraction. Drugs or mutations can modulate channel gating, ion conductance, or receptor assembly/expression.